RB1CC1 and breast carcinoma: It is important to note that the prognosis of 168 cases without any deficit in RB1CC1/RB1/p53 immunoreactivity was significantly better than that of 155 cases with deficits in any one of these three components (Log-rank test; Chi-Square value = 28.496, p<0.0001), and that very few increments in breast cancer-specific death in the former group occurred even after five years from clinical disease onset (Fig. 1C).